title: [Concomitant dosing of a H2 receptor antagonist (H2RA) with a triple therapy increases the cure rate of Helicobacter pylori infection].
authors.affiliation: Second Department of Internal Medicine, National Defense Medical College.
authors.forename: Keisuke
authors.initials: K
authors.lastname: Okudaira
authors.forename: Soichiro
authors.initials: S
authors.lastname: Miura
authors.forename: Takahisa
authors.initials: T
authors.lastname: Furuta
authors.forename: Mitsushige
authors.initials: M
authors.lastname: Sugimoto
authors.forename: Naohito
authors.initials: N
authors.lastname: Shirai
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000658:Amoxicillin / Q000627:therapeutic use; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics; D017291:Clarithromycin / Q000627:therapeutic use; D065731:Cytochrome P-450 CYP2C19; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D015738:Famotidine / Q000627:therapeutic use; D005745:Gastric Acidity Determination; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori; D006635:Histamine H2 Antagonists / Q000378:metabolism / Q000627:therapeutic use*; D006801:Humans; D064747:Lansoprazole; D006899:Mixed Function Oxygenases / Q000235:genetics; D009853:Omeprazole / Q000031:analogs & derivatives / Q000627:therapeutic use; D011110:Polymorphism, Genetic
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D004791:Enzyme Inhibitors; D006635:Histamine H2 Antagonists; D064747:Lansoprazole; D015738:Famotidine; D000658:Amoxicillin; D006899:Mixed Function Oxygenases; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D017291:Clarithromycin; D009853:Omeprazole